Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMPSA1)

• Drug Name: Tusamitamab ravtansine Drug Info
• Synonyms: SAR408701

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25	Phase 3	[1]
Aggressive cancer	2A00-2F9Z	Phase 2	[2]
Breast cancer	2C60-2C65	Phase 2	[2]
Gastric cancer	2B72	Phase 2	[3]

• Cross-matching ID: TTD Drug ID: DMMPSA1

Molecule-Related Drug Atlas

Drug(s) Targeting Carcinoembryonic antigen CEA (CD66e)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAR408701	DMXGE3O	Non-small-cell lung cancer	2C25.Y	Phase 3	[5]
IDM-2101	DMABRXY	Colorectal cancer	2B91.Z	Phase 2	[6]
CAP1-6D	DMEYIVW	Pancreatic cancer	2C10	Phase 2	[7]
Pentacea	DMGY5JC	Small-cell lung cancer	2C25.Y	Phase 2	[8]
GI-6207	DM72O6F	Thyroid cancer	2D10	Phase 2	[9]
CeaVac	DM6Z9BV	Colorectal cancer	2B91.Z	Phase 2	[10]
Labetuzumab I-131	DMNO5UE	Colorectal cancer	2B91.Z	Phase 2	[11]
AVX701	DMOPVIQ	Colorectal cancer	2B91.Z	Phase 1/2	[12]
CT84.66	DM6078F	Breast cancer	2C60-2C65	Phase 1/2	[13]
CAR-T cells targeting CEA	DM6VCPX	Colorectal cancer	2B91.Z	Phase 1/2	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carcinoembryonic antigen CEA (CD66e)	TTY6DTE	CEAM5_HUMAN	Not Available	[4]

References

• [1] ClinicalTrials.gov (NCT05245071) Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04659603) Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors. U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT05703555) INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701. U.S.National Institutes of Health.
• [4] Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425.
• [5] ClinicalTrials.gov (NCT02187848) Evaluation of SAR408701 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [6] Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
• [7] Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997 Oct 15;57(20):4570-7.
• [8] Antibody fragments: Hope and hype. MAbs. 2010 Jan-Feb; 2(1): 77-83.
• [9] Clinical pipeline report, company report or official report of GlobeImmune.
• [10] Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 1999 Sep;17(9):2889-5.
• [11] National Cancer Institute Drug Dictionary (drug id 692828).
• [12] Viral vector-based therapeutic cancer vaccines. Cancer J. 2011 Sep-Oct;17(5):359-71.
• [13] Technology evaluation: cT84.66, City of Hope. Curr Opin Mol Ther. 2004 Feb;6(1):90-5.
• [14] ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.